# A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

> **NCT04296890** · PHASE3 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 106 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Mirvetuximab Soravtansine

## Key facts

- **NCT ID:** NCT04296890
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-23
- **Primary completion:** 2021-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04296890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04296890, "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04296890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*